Zouari Raida, Hamden Khaled, Feki Abdelfattah El, Chaabouni Khansa, Makni-Ayadi Fatma, Kallel Choumous, Sallemi Fahima, Ellouze-Chaabouni Semia, Ghribi-Aydi Dhouha
Enzymes and Bioconversion Research Unit, National School of Engineers of Sfax (ENIS), Tunisia; Higher Institute of Biotechnology of Sfax (ISBS), Tunisia.
Animal Ecophysiology Laboratory, Faculty of Sciences of Sfax (FSS), Tunisia.
Biomed Pharmacother. 2016 Dec;84:323-329. doi: 10.1016/j.biopha.2016.09.023. Epub 2016 Sep 22.
This study was aimed to assess the plausible anti-obesity effects of Bacillus subtilis SPB1 crude lipopeptide biosurfactant on high fat high fructose diet-fed rats (HFFD). Male Wistar rats were divided into five groups with the following treatment schedule: normal diet (CD), HFFD, HFFD supplemented with SPB1 biosurfactant from the first day of the experiment (HFFD+Bios1, 10mg/kg/day), HFFD receiving standard drug (HFFD+Torva, 10mg/kg/day) or SPB1 biosurfactant (HFFD+Bios2, 10mg/kg/day) during the last 4 weeks of the study. The results showed an increase in body weight of HFFD by ∼19% as compared to controls (CD). Moreover, serum lipase activity underwent a threefold increase which led to an increase in the levels of total cholesterol (T-Ch), triglycerides (TG) and LDL-cholesterol (LDL-Ch) in serum of untreated HFFD, as well as a rise in the calculated atherogenic index (AI). Furthermore, liver dysfunction indices such as AST, ALT, CPK, LDH, GGT, ALP and T-Bilirubins exhibited remarkable increases in serum of HFFD as compared to controls (CD). Whereas, the administration of Bacillus subtilis SPB1 biosurfactant to HFFD improved the body weight gain and serum lipids profile and reverted back near normal the activities of lipase and liver toxicity indicators. In addition, notable protective and curative effects were reported in liver tissues. Overall, these results suggest that the lipopeptides biosynthesized by Bacillus subtilis SPB1 achieved an anti-obesity effect through the inhibition of lipid digestive and liver dysfunction enzymes.
本研究旨在评估枯草芽孢杆菌SPB1粗脂肽生物表面活性剂对高脂高果糖饮食喂养大鼠（HFFD）可能的抗肥胖作用。雄性Wistar大鼠分为五组，采用以下处理方案：正常饮食（CD）、HFFD、从实验第一天开始补充SPB1生物表面活性剂的HFFD（HFFD+Bios1，10mg/kg/天）、在研究的最后4周接受标准药物（HFFD+Torva，10mg/kg/天）或SPB1生物表面活性剂（HFFD+Bios2，10mg/kg/天）的HFFD。结果显示，与对照组（CD）相比，HFFD组大鼠体重增加了约19%。此外，血清脂肪酶活性增加了两倍，导致未处理的HFFD大鼠血清中总胆固醇（T-Ch）、甘油三酯（TG）和低密度脂蛋白胆固醇（LDL-Ch）水平升高，以及计算得出的动脉粥样硬化指数（AI）升高。此外，与对照组（CD）相比，HFFD大鼠血清中的肝功能指标如AST、ALT、CPK、LDH、GGT、ALP和总胆红素显著升高。而给HFFD大鼠施用枯草芽孢杆菌SPB1生物表面活性剂可改善体重增加和血清脂质谱，并使脂肪酶活性和肝毒性指标恢复到接近正常水平。此外，在肝脏组织中报告了显著的保护和治疗作用。总体而言，这些结果表明，枯草芽孢杆菌SPB1生物合成的脂肽通过抑制脂质消化酶和肝功能障碍酶实现了抗肥胖作用。
